A TGFB2/TNF-induced in vitro model of proliferative vitreoretinopathy (PVR) using ARPE-19 cells confirms nicotinamide as an inhibitor of EMT and VEGFA secretion. The gene discussed is TGFB2; the disease is CAPN5-related vitreoretinopathy.